Dr. Ali El-Ghamrawy, Chairman of the Egyptian Drug Authority (EDA), held a meeting with representatives of Abbott, headed by Dr. Mazen Hassan Bashir, Regional Vice President for the Middle East, Africa, and Pakistan. The meeting was attended by Dr. Mohamed Kandil, Regional Director for Abbott Egypt, Saudi Arabia, and Africa, and Dr. Giulio Amori, Global Vice President for Operations and Manufacturing at Abbott.
The meeting was held within the framework of the Authority’s commitment to strengthening strategic partnerships with leading global pharmaceutical companies and supporting initiatives aimed at localizing pharmaceutical manufacturing in Egypt.
During the meeting, both sides reviewed existing areas of cooperation between the Egyptian Drug Authority and Abbott, as well as opportunities to further develop this collaboration in the coming phase. Discussions also addressed Abbott’s future strategic plans for localization, including the transfer of advanced technologies, enhancement of local manufacturing capabilities, support of supply chains, and investment in the development of national competencies and human capital, in line with the state’s vision to establish a strong, competitive, and sustainable pharmaceutical industry.
Dr. Ali El-Ghamrawy emphasized that localizing pharmaceutical manufacturing in Egypt is not merely an economic objective, but a pivotal step toward ensuring the sustainable availability of medicines and safeguarding the health of Egyptian citizens. He noted that the Authority will continue to support all initiatives that enhance local market capabilities and strengthen the healthcare system, stressing that pharmaceutical security is a national priority that requires the concerted efforts of all relevant stakeholders.
For their part, Abbott representatives affirmed that this cooperation reflects the company’s commitment to supporting the Egyptian state’s efforts to develop the healthcare system by providing innovative healthcare solutions and ensuring access to high-quality medicines. This, they noted, contributes to achieving the highest standards of healthcare and guarantees the delivery of safe and effective treatments to every patient in Egypt.
Abbott representatives also commended the leading role of the Egyptian Drug Authority in regulating the pharmaceutical sector and strengthening the healthcare system. They highlighted that the Authority’s support for pharmaceutical localization and the development of local capabilities reflects a clear strategic vision and fosters a stable investment environment, contributing to the achievement of local self-sufficiency and the provision of medicines to Egyptian citizens in accordance with the highest quality standards.
The meeting comes as a continuation of the constructive partnership between the Egyptian Drug Authority and Abbott, aiming to explore ways to enhance cooperation in line with the state’s direction toward localizing pharmaceutical manufacturing and supporting plans to achieve self-sufficiency. This cooperation contributes to the development of the healthcare sector, the strengthening of pharmaceutical security, and the creation of added value for the national economy.